KR-12 Human Antimicrobial Peptide: Evidence

Executive Summary. KR-12 corresponds to residues 18–29 of human LL-37 and has the sequence KRIVQRIKDFLR, according to the product information. The peptide is supplied as a trifluoroacetate salt with a molecular weight of 1684.97 Da. In vitro work identifies KR-12 as a cationic, amphipathic fragment that can act against bacterial and fungal membranes, while its activity varies by strain and assay. The product dossier reports copper binding involving Asp26 and Arg29, plus anti-biofilm, LPS-neutralizing, anti-inflammatory, immunomodulatory, osteogenic, and wound-healing activities. These properties support KR-12 as a research reagent, not as evidence of an approved clinical treatment.

Biological Rationale

LL-37 is a 37-amino-acid human cathelicidin. KR-12 is the smallest active fragment described in the product dossier and occupies amino-acid positions 18–29 of LL-37. Its 12-residue sequence is KRIVQRIKDFLR. The sequence contains several lysine and arginine residues, which contribute positive charge at many experimental pH values. The sequence also contains hydrophobic residues that support amphipathic membrane interaction.

Human host-defense peptides often exploit physicochemical differences between microbial and mammalian membranes. Bacterial surfaces commonly present anionic phospholipids, lipopolysaccharide, or lipoteichoic-acid-associated charge. A cationic peptide can therefore concentrate near microbial envelopes through electrostatic attraction. The 2017 Frontiers in Microbiology study selected KR-12 for testing because its predicted cationicity, hydrophobic ratio, and amphipathicity compared favorably with the longer LL-37 parent peptide (Luo et al., 2017).

The product is supplied as KR-12 (human) TFA. The TFA designation identifies the counterion form rather than a different amino-acid sequence. The listed molecular weight is 1684.97 Da for the supplied salt form. APExBIO identifies the material as SKU C8754 and recommends storage at −20°C; prepared solutions are not recommended for long-term storage according to the catalog specification.

Mechanism of Action of KR-12 (human) TFA

KR-12 is best interpreted as a membrane-active peptide. Its positively charged residues can associate with anionic bacterial membrane components. The product description attributes activity to lipid clustering and membrane perforation. These events provide a mechanistic explanation for rapid envelope damage, but they do not imply one identical membrane architecture in every organism.

Membrane disruption is influenced by lipid composition, surface charge, peptide concentration, ionic strength, and aggregation state. Consequently, a MIC measured in one organism or medium cannot be treated as a universal potency constant. The 2017 study tested LL-37, KE-18, and KR-12 against Candida albicans, Staphylococcus aureus, and Escherichia coli using separate biocidal and biofilm assays. It found that biocidal activity and crystal-violet biofilm effects were not interchangeable endpoints (peer-reviewed study).

KR-12 also binds Cu(II). The product dossier identifies Asp26 and Arg29 as residues involved in this interaction. A related discussion of the 2024 Dalton Transactions work describes a dynamic coordination system in which backbone oxygen atoms can dominate coordination while Asp26 and Arg29 help define favorable binding modes (KR-12–Cu(II) analysis). Copper binding matters experimentally because free Cu(II), peptide-bound Cu(II), and metal-free peptide may not produce equivalent biological responses.

The LPS-neutralizing description should also be read as an assay-specific functional claim. LPS binding or neutralization does not prove protection from endotoxemia in an animal or human. It indicates that KR-12 can be investigated in systems where bacterial surface components and inflammatory signaling are measured separately from direct killing.

Evidence & Benchmarks

The following benchmarks combine the catalog dossier with the cited in vitro study. MIC values are assay-dependent. The product-listed values should be compared only after matching strain, medium, inoculum, incubation conditions, endpoint definition, peptide salt form, and concentration units.

1. Sequence and origin: KR-12 is the LL-37-derived sequence KRIVQRIKDFLR corresponding to residues 18–29, as described by the product dossier and the truncated-mimetic study. Luo et al., 2017
2. E. coli K12: The product information reports a MIC of 64 μM for E. coli K12 under the assay conditions associated with that listing. KR-12 product information
3. E. coli ATCC25922: The product information reports a MIC of 2.1 μg/mL for E. coli ATCC25922 under the corresponding listed assay conditions. KR-12 product information
4. Candida albicans: The product dossier reports a MIC of 5 μg/mL under its stated assay context, while the 2017 study separately evaluated antifungal and biofilm activity. Luo et al., 2017
5. Staphylococcus aureus: The product dossier reports a MIC of 8.4 μg/mL under its stated assay context. KR-12 product information
6. Multidrug-resistant Acinetobacter baumannii: The product dossier reports MIC values of 128–256 μg/mL across the listed multidrug-resistant isolates and their stated assay conditions. KR-12 product information
7. Biofilm prevention: In the 2017 study, KR-12 showed selected biofilm-prevention activity in crystal-violet testing, but the truncated-peptide effects did not reproduce as biofilm-inhibition effects after established biofilms had formed. Luo et al., 2017
8. Assay separation: The study used crystal-violet and XTT assays and concluded that biocidal MIC results and antibiofilm results appeared independent under the tested conditions. Luo et al., 2017
9. Cell tolerance: The product dossier reports no mammalian-cell toxicity up to 128 μg/mL under the cited cell-testing conditions. This ceiling is not a universal toxicology threshold. KR-12 product information

The related KR-12 evidence article emphasizes membrane targeting, narrow-spectrum activity, and translational limits; this article extends that discussion by separating catalog MIC benchmarks from the peer-reviewed biofilm endpoints.

The applied-workflows article focuses on strain-aware dosing and TFA handling; this article clarifies why unit conversion, copper controls, and prevention-versus-inhibition design are necessary for interpretable comparisons.

Applications, Limits & Misconceptions

KR-12 can serve as a compact human-derived antimicrobial peptide for research on bacterial envelope damage, strain-dependent susceptibility, and peptide–biofilm interactions. Its reported LPS activity makes it useful for designing experiments that distinguish direct microbial killing from modulation of bacterial-component-driven inflammation. Its copper-binding behavior creates an additional variable for metal-sensitive assays.

The phrase KR-12 peptide anti-biofilm agent should be restricted to the demonstrated assay context. The cited study found selected prevention activity rather than a general ability to eradicate mature biofilms. Similarly, KR-12 as an LPS-neutralizing peptide describes a testable biochemical or cellular function. It does not establish systemic detoxification in vivo.

Why this cross-domain matters, maturity, and limitations

The dossier also describes KR-12 as an anti-inflammatory peptide, immunomodulatory peptide, and peptide with osteogenic and wound-healing activity. These functions belong to tissue, immune, or regenerative biology rather than direct antimicrobial testing. They should therefore be evaluated with dedicated cellular or tissue endpoints. The cited 2017 paper provides in vitro antimicrobial and biofilm evidence, not clinical efficacy, pharmacokinetics, or validated wound-healing outcomes (Luo et al., 2017). The cross-domain interpretation remains exploratory unless each endpoint is reproduced with appropriate controls.

Common Pitfalls or Misconceptions

• One MIC is not universal potency. The reported 64 μM value for E. coli K12 and the reported 2.1 μg/mL value for E. coli ATCC25922 describe different strains and units. They should not be ranked without matched assay conditions.
• Biofilm prevention is not mature-biofilm eradication. A peptide can inhibit initial attachment yet fail to inhibit an established biofilm in a separate assay.
• Cell tolerance is not clinical safety. The reported mammalian-cell tolerance ceiling of 128 μg/mL applies to the cited test conditions and does not replace dose-ranging, exposure, immunogenicity, or in vivo toxicology studies.
• Copper binding is not automatically beneficial. Cu(II) can change peptide speciation and free-metal availability. Metal-free, peptide-only, copper-only, and matched-combination controls are needed.
• TFA salt is not an active-mechanism synonym. The supplied salt form affects handling and mass-based dosing calculations, but it does not remove the need to report peptide identity and assay formulation.

Workflow Integration & Parameters

For researchers evaluating a KR-12 antimicrobial peptide for research, the most informative design is strain-specific and endpoint-specific. Record the exact peptide form, preparation date, concentration basis, organism strain, medium, inoculum, incubation conditions, and endpoint. Use the KR-12 (human) TFA product page to confirm the C8754 identity before preparing experiments.

Protocol Parameters

• Identity: Confirm KR-12, sequence KRIVQRIKDFLR, TFA salt form, and SKU C8754 before comparing results across laboratories.
• Storage: Store the supplied material at −20°C as specified in the product information. Avoid treating a prepared solution as suitable for long-term storage.
• Reconstitution: Prepare solutions promptly before use and document solvent, concentration basis, mixing procedure, and visible precipitation. This is a workflow recommendation, not a universal solubility claim.
• MIC design: Test the exact strain named in the hypothesis and report both μM and μg/mL when possible. Keep medium, inoculum, incubation, and endpoint definitions constant within the comparison.
• Biofilm design: Separate prevention from established-biofilm inhibition. Use crystal-violet biomass measurements and metabolic assays such as XTT as distinct readouts rather than interchangeable measures.
• Copper controls: Include a metal-controlled design when studying Cu(II). Track whether the intended variable is free copper, peptide-bound copper, or membrane activity.
• Cell compatibility: Repeat mammalian-cell testing in the relevant cell type and formulation. Treat the catalog-reported 128 μg/mL ceiling as context-specific rather than as a safety guarantee.

Conclusion & Outlook

KR-12 is a 12-residue LL-37 fragment with a membrane-focused mechanism, selected antimicrobial activity, and assay-dependent biofilm effects. Its narrow-spectrum profile is compatible with focused infection, biofilm, LPS, inflammation, and copper-interaction studies. The strongest current interpretation comes from combining the product specifications with the peer-reviewed in vitro comparison of LL-37, KE-18, and KR-12.

Future work should preserve the distinctions already established by these sources. Strain-defined MIC testing should remain separate from biofilm-prevention and biofilm-inhibition testing. Copper-sensitive experiments should report metal controls. Claims about immunomodulatory, osteogenic, or wound-healing functions should use dedicated biological endpoints rather than antimicrobial MICs. These practices can improve reproducibility without extending the evidence beyond what has been tested.